Solid Tumor Testing in Malaysia Trends and Forecast
The future of the solid tumor testing market in Malaysia looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1641.7 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The solid tumor testing market in Malaysia is also forecasted to witness strong growth over the forecast period. The major drivers for this market are an increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.
• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
Emerging Trends in the Solid Tumor Testing Market in Malaysia
The market for testing solid tumors is changing rapidly in Malaysia due to the growing adoption of technology, enhancements in the healthcare structure, and increasing awareness of cancer screening. As the number of cancer cases rises, particularly among older people, more sophisticated and easier diagnostic measures are in demand. The emergence of new technologies and testing processes continues to drive the market toward more precise medicine and diagnostics. Below are five major trends affecting solid tumor testing in Malaysia.
• Acceptance of Liquid Biopsy: Liquid biopsy is emerging as a non-invasive technique for the early identification of malignant solid tumors. This trend is changing the landscape of cancer diagnosis in Malaysia by offering a less invasive and painful alternative to traditional biopsy techniques. It is called “liquid biopsy” because the detection of primary lung, colorectal, breast, and other cancers can be done by monitoring treatment responses and detecting recurrences through blood samples. As the cost of technology lowers, its integration into regular cancer screenings is likely to increase.
• Using AI in Diagnostics: AI is being used in the discovery and monitoring of solid tumors in Malaysia. AI tools, such as machine learning algorithms, analyze CT and MRI scans. AI analyzes medical imaging data much faster and with greater precision than human radiologists. This not only reduces errors in diagnosis but also improves the efficiency of identifying early-stage tumors. AI also enables better segmentation of tumor volume, improving the accuracy of staging and treatment planning, thereby enhancing patient outcomes.
• Increasing Adoption of Genomic Profiling for Targeted Therapy: Genomic profiling is becoming a major trend in Malaysia’s solid tumor testing market because it supports targeted cancer therapies specific to the tumor’s genotype. Genomic profiling helps oncologists identify mutations and molecular markers for more precise and effective cancer treatments with fewer adverse effects. This is crucial for breast, lung, and colon cancers, as these are cancers where targeted therapies have been established as the standard practice. Malaysia’s cancer treatment will greatly benefit from the wider availability of genomic profiling, which will aid in revolutionizing cancer treatment in the country.
• Government Contributions and Healthcare Programs: The Malaysian government is aware of its role in improving solid tumor testing infrastructure. National cancer screening programs, additional funding for research, and policies promoting solid tumor testing methods using sophisticated technologies are all part of the effort. The goal is to increase detection rates, reduce the cancer burden, and improve cancer survival rates. Government backing is also essential for making newer diagnostic technologies available to a broader population.
• Advanced Systems for Robotic Biopsy Imaging: Systems with advanced imaging and robotic-assisted biopsy are becoming increasingly available in Malaysia’s solid tumor testing market. These systems provide advanced technology with minimal discomfort to patients, leading to quicker recovery and reduced surgical complications. As more people seek less invasive procedures, these technologies are changing the diagnostic paradigm by offering patient-friendly and less complex treatment solutions. The continued adoption of these techniques is expected to improve the quality of care received by cancer patients.
Trends like the emerging use of liquid biopsy, artificial intelligence, genomic profiling, government policies, and a general move toward less invasive methods are reshaping the solid tumor testing market in Malaysia. These trends are transforming how patients are diagnosed and treated, leading to a more innovative approach to cancer care. With every advancement, the Malaysian healthcare system is becoming better equipped to provide effective and tailored treatment for a growing cancer-afflicted population, improving overall patient care. Ongoing efforts in the country give hope that the future of solid tumor testing in Malaysia will be one of ease and efficiency, radically changing the landscape for cancer diagnosis and treatment.
Recent Developments in the Solid Tumor Testing Market in Malaysia
The solid tumor testing market in Malaysia is evolving due to the lack of innovative and accurate diagnostic cancer tools. With rising incidences of cancer, there is an increasing need for advanced testing solutions that are efficient and easily accessible. Below are five key developments that are changing the solid tumor testing market in Malaysia.
• Introduction of Next-Generation Sequencing (NGS): In Malaysia, solid tumor testing is adopting next-generation sequencing (NGS) technology, allowing for a thorough evaluation of the genetic mutations present in tumor samples. This advancement enables oncologists to alter therapies to match specific genetic changes. Lung, colorectal, and breast cancers are among those that benefit from NGS-targeted treatments. The increased use of NGS is expected to lead to enhanced cancer diagnoses, improved treatment options, and better health outcomes for Malaysian cancer patients.
• Government Funding for Cancer Screening Programs: The Malaysian government has committed significant resources to initiatives that support cancer screening aimed at early detection of solid tumors. These programs target high-risk populations and provide subsidized or complimentary screening services for breast, cervical, and colorectal cancer. Government funding has expanded the use of screening programs that employ advanced tools like mammography, colonoscopy, and even newer technologies like liquid biopsy. These approaches are increasing early diagnosis rates, reducing late-stage cancer cases, and improving survival rates in Malaysia.
• Enhancing Networking in Solid Tumor Testing with International Institutes: Malaysia is expanding its collaborations with foreign cancer research institutions to enhance its capabilities in solid tumor testing. These partnerships facilitate the exchange of knowledge, technology, and resources, allowing local providers to use advanced testing methods. Collaboration with foreign institutions has also led to the establishment of specialized cancer centers in Malaysia, which are equipped with the latest diagnostic and therapeutic technologies. These partnerships are fostering the growth of the solid tumor testing market and improving the quality of cancer care in Malaysia.
• Growth in Cancer Diagnostic Centers: In Malaysia, the number of diagnostic centers has increased remarkably in recent years, reflecting a growing focus on cancer care. These centers are equipped with modern imaging and molecular diagnostic devices such as PET, MRI, and genomic testing technologies. The availability of more diagnostic centers has improved early screening and accurate diagnoses among patients. The proliferation of these centers is expected to expand access to advanced solid tumor testing services for a larger segment of the Malaysian population, improving cancer care services.
• Development of AI-Driven Diagnostic Tools: AI-driven diagnostic tools have been increasingly incorporated into Malaysia’s healthcare system to improve the accuracy and speed of solid tumor identification. Machine learning algorithms scan imaging data from CT, MRI, and X-ray machines for potential mutations within the images. With AI’s use, diagnostic errors are decreasing, tumor characterization is being enhanced, and interventions are being implemented at earlier stages. If properly harnessed, AI technology can significantly increase the accuracy of cancer diagnoses, improving treatment options and overall healthcare outcomes for patients in Malaysia.
Recent changes in Malaysia’s solid tumor testing market, including the use of NGS, increased government funding for cancer screening programs, collaborations with foreign research institutions, the development of new diagnostic center infrastructure, and the growing use of AI-driven tools, symbolize a significant shift in cancer care. These developments are improving access to solid tumor testing, enhancing the accuracy of results, and helping save more lives affected by cancer. As these changes continue to be implemented, Malaysia’s cancer care system is being transformed into a more modern and efficient one, providing better service to the population and reshaping the public health system as a whole.
Strategic Growth Opportunities for Solid Tumor Testing Market in Malaysia
Growth in the solid tumor testing market in Malaysia is imminent, owing to developed technologies and varying healthcare needs. As Malaysia tackles the surge in cancer cases, investment and adoption of new advanced testing methodologies are of primary concern. This presents growth prospects focusing on key areas like diagnostic precision, early intervention, and customized treatment plans. We outline five Raman spectroscopy growth opportunities in solid tumor testing that exemplify reasons for market growth.
• Adoption of Liquid Biopsy for Early Diagnosis: Liquid biopsy is developing as a non-invasive and reliable method for early identification of solid tumors. This method identifies specific cancer-associated genetic anomalies from the blood, making it possible to diagnose lung, colorectal, and breast cancers much earlier in their progression. Malaysia can adopt this approach to enhance early detection rates and lower overall treatment costs by diagnosing cancer at manageable stages with less invasive and expensive interventions.
• Advancement of AI and Machine Learning: AI and machine learning are changing how the solid tumor screening market works in Malaysia. With the use of AI tools, CT scans, MRIs, and X-rays can be analyzed to detect the presence of a tumor far more efficiently than a radiologist can. With the advancement of AI technology in tumor testing, it is possible to deliver unparalleled diagnostic accuracy, a decrease in mistakes, and rapid detection of solid tumors. Additionally, AI-powered technologies assist in formulating customized treatment plans, resulting in patient satisfaction and better health outcomes.
• Adoption of Genomic Profiling for Targeted Therapy: The application of genomic profiling in Malaysia is opening new doors for more personalized cancer therapies, which will lead to market growth. Genomic profiling helps in determining the particular mutations and biomarkers in a patient’s tumor. This specialized testing guides the choice of targeted therapeutics, which is very important for breast, lung, and colon cancers. The increasing use of genomic profiling will certainly improve treatment plans, treatment response, and outcome measures in patients that oncologists manage in Malaysia, resulting in better cancer care practices.
• Broadening National Cancer Screening Initiatives: The screening program’s recent moves involve bolstering national cancer screening protocols, which increases cancer morbidity and mortality prevention among relevant target demographic groups in Malaysia. By increasing the availability of affordable screening instruments such as mammograms, colonoscopies, and liquid biopsies, the government hopes to lower cancer death rates. This creates an opportunity for growth by stimulating demand for diagnostic services and increasing public knowledge on cancer screening. Screening programs tend to foster more favorable outcomes, such as advanced diagnoses, higher survival rates among patients, and lower costs in healthcare in the long run.
• Increase in Robotic-Assisted Biopsy Machines Within Malaysia: Malaysia has an opportunity to grow its solid tumor biopsy market through robotic-assisted biopsy systems. These sophisticated systems improve patient comfort during the biopsy procedure due to enhanced tumor sampling accuracy. More patients are needing robotic-assisted biopsy systems because these procedures have fewer intraoperative complications due to significantly lower recovery times, fewer complications, and reduced human errors in tumor sampling. The increased accuracy and efficiency in the diagnosis of solid tumors would improve patient care and healthcare productivity in Malaysia.
The solid tumor testing market in Malaysia is expanding with various key applications such as liquid biopsy, AI and ML-based diagnostics, genomic profiling, national screening programs, and robotic surgical systems. These technologies are enhancing the accuracy, speed, and personalization of cancer diagnostics and treatments, which subsequently leads to improved outcomes and expansion for the market. With advancements in Malaysia’s healthcare system, these innovations will be instrumental in the transformation of cancer care in the country.
Solid Tumor Testing Market in Malaysia Driver and Challenges
The solid tumor testing market in Malaysia has incorporated numerous drivers and challenges, such as technological, economic, and regulatory changes. These aspects affect the market structure and have profound consequences on the integration of solid tumor testing into the healthcare system. These drivers and challenges are important because they will help in realizing development prospects as well as removing obstacles that can impede market growth. Some of the primary drivers and challenges affecting this market are listed below.
The factors responsible for driving the solid tumor testing market in Malaysia include:
• New Innovations in Tumor Testing Technology: AI-based imaging, genomic profiling, and even liquid biopsy have made solid tumor testing more affordable and further enhanced the industry. These innovations allow for the detection of tumors at an earlier stage, which aids in improving patient prognoses while also lowering treatment expenses. With the expansion of healthcare technologies in Malaysia, we can expect that diagnostic speed and precision for cancer will increase and subsequently allow for early-stage cancer diagnosis and tailored therapy implementations.
• Increased Number of Cancer Patients and Their Understanding of the Disease: Cancer’s growing prevalence in Malaysia, particularly among senior citizens, has put substantial pressure on available resources, resulting in solid tumor testing requirements. With the rise of knowledge around cancer and procedures related to it, patients are actively seeking tests and treatments. This is supported by nationwide awareness programs and government campaigns advocating for cancer testing. The recognition of cancer as a paramount public health concern is stimulating the proliferation of test offerings, which in turn creates a surge in demand for such services in both developed and developing regions.
• Support from the Government as an Investment in the Health Sector: The government of Malaysia is modernizing the country’s healthcare system, which is beneficial for the solid tumor testing business in the country. More aggressive policies targeting cancer screening, additional funding for research projects, and the embracing of more advanced technologies are improving the availability of solid tumor testing. Government programs that support and facilitate the incorporation of new diagnostic technologies into public health institutions are providing wider access to quality testing services, which increases market attention.
• Trends in Personalized Medicine Development in Malaysia: Customized medicine, which modifies treatment according to the genetic makeup of an individual’s tumor, is on the rise in the Malaysian healthcare industry. The adoption of genomic profiling and molecular diagnostics to treat solid tumors is increasing, and it is expected that a greater number of patients will have more tailored treatment approaches. The rise of personalized medicine is creating greater demand for new and advanced diagnostic services and novel opportunities for developments in the solid tumor testing industry.
• Enhanced Access to Infrastructure and Modern Medical Facilities: Improved access to infrastructure and modern medical facilities is contributing toward the growth of the market in Malaysia. There has been an expansion and replacement of older diagnostic centers, and modern facilities such as cancer screening and diagnosis centers have opened. This, in turn, has raised the demand for cancer screening and diagnosis. The increasing prevalence of advanced imaging, AI-based diagnostics, and even genomics is propelling the efficiency and accuracy of cancer diagnostics, thus contributing to market growth across the country.
Challenges in the solid tumor testing market in Malaysia are:
• Lack of Financial Resources and Advanced Diagnostic Technologies: Although very beneficial, technologies such as liquid biopsy and AI imaging come with a high initial cost, which creates an economic barrier for most people. Practically every public healthcare institution in Malaysia runs into budget constraints that deeply limit the scope of technology available. Unfortunately, this means that the most advanced testing solutions are the most difficult to provide due to a lack of access for low-income and rural populations.
• Regulatory Processes and Barriers: The procedures for regulating and approving new technologies are often very tedious, which hinders the development of new solutions that could benefit the Malaysian market. The government is willing to embrace and support technology; however, the regulation of medical devices and diagnostics tends to be cumbersome and time-consuming. Delays in approvals or the adoption of new technology can stifle market growth, directly impacting patients’ access to advanced cancer diagnostic technology and tools.
• Missing Workforce Skill Set: The same issue of lack of talent exists in Malaysia when it comes to solid tumor testing, which is one of the many challenges the cancer care market faces in Malaysia. Having highly advanced techniques like genomic profiling and liquid biopsy performed requires specialized knowledge. A limitation in cancer care services is the lack of trained oncologists, pathologists, and laboratory technologists skilled in these areas. This issue is likely to increase the time required to make a diagnosis and lower the quality of cancer care, thus inhibiting market growth.
As with any other market, the solid tumor testing market in Malaysia has its set of drivers and challenges that cannot be neglected. The market is developing significantly due to efforts made in technology and government policies, as well as the increasing shift toward personalized medicine. However, the market also faces considerable challenges, such as expensive pricing, complex regulations, and a lack of trained personnel. Overcoming these challenges while taking advantage of the identified drivers will be key to maintaining growth in the solid tumor testing market as well as improving cancer treatment in Malaysia.
List of Solid Tumor Testing Market in Malaysia Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, solid tumor testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Solid Tumor Testing Market in Malaysia by Segment
The study includes a forecast for the solid tumor testing market in Malaysia by type, application, and end use.
Solid Tumor Testing Market in Malaysia by Type [Analysis by Value from 2019 to 2031]:
• Genetic Testing
• Conventional Testing
Solid Tumor Testing Market in Malaysia by Application [Analysis by Value from 2019 to 2031]:
• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others
Solid Tumor Testing Market in Malaysia by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions
Features of the Solid Tumor Testing Market in Malaysia
Market Size Estimates: Solid tumor testing in Malaysia market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Solid tumor testing in Malaysia market size by type, application, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, application, and end use for the solid tumor testing in Malaysia.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing in Malaysia.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the solid tumor testing market in Malaysia?
Answer: The major drivers for this market are increase in the utilization of supplements and steroids and increase in unhealthy habits, such as smoking and alcohol consumption.
Q2. What are the major segments for solid tumor testing market in Malaysia?
Answer: The future of the solid tumor testing market in Malaysia looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets.
Q3. Which solid tumor testing market segment in Malaysia will be the largest in future?
Answer: Lucintel forecasts that melanoma is expected to witness the highest growth over the forecast period due to growing incidence of skin tumors and related conditions globally.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market in Malaysia by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), and end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Solid Tumor Testing Market in Malaysia, Solid Tumor Testing Market in Malaysia Size, Solid Tumor Testing Market in Malaysia Growth, Solid Tumor Testing Market in Malaysia Analysis, Solid Tumor Testing Market in Malaysia Report, Solid Tumor Testing Market in Malaysia Share, Solid Tumor Testing Market in Malaysia Trends, Solid Tumor Testing Market in Malaysia Forecast, Solid Tumor Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.